多发性硬化症患者血清Irisin,Nesfatin-1和YKL-40水平检测对临床病情评估的价值研究

Value of Serum Irisin,Nesfatin-1 and YKL-40 Level Detection in Clinical Evaluation of Multiple Sclerosis Patient

目的探讨血清鸢尾素(Irisin)、新饱食分子蛋白-1(Nesfatin-1)和甲壳质酶蛋白40(YKL-40)水平检测在多发性硬化症(MS)患者病情评估中的作用。方法纳入2017年8月~2023年11月在邯郸市第一医院就诊的MS患者160例作为研究对象,依据临床分型分为缓解期组(n=115)和进展期组(n=45);依据病情严重程度分为轻度组(n=109)和重度组(n=51)。采用ELISA法检测血清中Irisin,Nesfatin-1和YKL-40水平;采用Pearson分析MS患者血清Irisin,Nesfatin-1和YKL-40水平与扩展致残量表(EDSS)评分的相关性;采用多因素Logistic回归分析MS病情严重程度的影响因素;采用ROC曲线分析血清Irisin,Nesfatin-1和YKL-40水平对于MS患者病情进展的评估价值。结果进展期组MS患者血清Irisin(8.25±2.17 ng/ml),Nesfatin-1(5.94±1.76 ng/ml)水平低于缓解期组(14.94±3.58ng/ml,9.92±2.15 ng/ml),YKL-40(42.98±10.89 ng/ml)水平高于缓解期组(22.78±7.95 ng/ml),差异具有统计学意义(t=11.709,11.048,12.956,均P<0.05)。重度组MS患者血清Irisin(8.86±2.21 ng/ml),Nesfatin-1(6.32±1.91ng/ml)水平低于轻度组(15.02±4.42 ng/ml,9.96±2.30 ng/ml),病程(5.84±1.65年)和YKL-40(37.28±10.15 ng/ml)水平高于轻度组(3.65±1.45年,24.34±7.62 ng/ml),差异具有统计学意义(t=9.407,9.823,8.514,8.971,均P<0.05)。MS患者血清Irisin,Nesfatin-1与EDSS评分呈负相关(r=-0.504,-0.517,均P<0.05),YKL-40与EDSS评分呈正相关(r=0.509,P<0.05)。Irisin(OR=0.724,95%CI:0.589~0.889)和Nesfatin-1(OR=0.813,95%CI:0.669~0.945)是MS患者病情进展的保护因素,YKL-40(OR=2.964,95%CI:1.795~4.894)是MS患者病情进展的危险因素(均P<0.05)。血清Irisin,Nesfatin-1和YKL-40水平评估MS患者病情进展的AUC分别为0.844,0.849和0.823,均低于三者联合预测的AUC(0.957)(Z=3.158,3.096,3.324,均P<0.05)。结论血清Irisin,Nesfatin-1和YKL-40检测水平可有效评估多发性硬化症患者病情进展。

Objective To explore the role of serum Irisin,Nesfatin-1 and chitinase like protein 40(YKL-40)levels detection in evaluating the condition of patients with multiple sclerosis(MS).Methods A total of 160 MS patients who visited the First Hospital of Handan City from August 2017 to November 2023 were selected as the study subjects.According to clinical classification,they were separated into a remission group(n=115)and a progression group(n=45),and according to the severity of condition,they were separated into a mild group(n=109)and a severe group(n=51).ELISA method was applied to detect the levels of Irisin,Nesfatin-1 and YKL-40 in serum.Pearson was applied to analyze the correlation between serum Irisin,Nesfatin-1,YKL-40 levels and expanded disability status scale(EDSS)score in MS patients.Multivariate Logistic regression was applied to analyze the influencing factors of Ms Necerity.ROC curve was applied to analyze the evaluation value of serum Irisin,Nesfatin-1 and YKL-40 levels for the progression of MS patients.Results In the advanced stage group,the serum levels of Irisin(8.25±2.17 ng/ml)and Nesfatin-1(5.94±1.76 ng/ml)in MS patients were lower than those in the remission stage group(14.94±3.58 ng/ml,9.92±2.15 ng/ml),while the YKL-40(42.98±10.89 ng/ml)level was higher than that in the remission stage group(22.78±7.95 ng/ml),and the differences were statistically significant(t=11.709,11.048,12.956,all P<0.05).In the severe group,the serum levels of Irisin(8.86±2.21 ng/ml)and Nesfatin-1(6.32±1.91 ng/ml)in MS patients were lower than those in the mild group(15.02±4.42 ng/ml,9.96±2.30 ng/ml),while the disease course(5.84±1.65 years)and YKL-40(37.28±10.15 ng/ml)levels were higher than those in the mild group(3.65±1.45 years,24.34±7.62 ng/ml),and the differences were statistically significant(t=8.514,9.407,9.823,8.971,all P<0.05).Serum Irisin and Nesfatin-1 levels in MS patients were negatively correlated with EDSS scores(r=-0.504,-0.517,all P<0.05),while YKL-40 levels were positively correlated with EDSS scores(r=0.509,P<0.05).Irisin(OR=0.724,95%CI:0.589~0.889)and Nesfatin-1(OR=0.813,95%CI:0.669~0.945)were protective factors for disease progression in MS patients,while YKL-40(OR=2.964,95%CI:1.795~4.894)was a risk factor for disease progression in MS patients(all P<0.05).The AUCs of serum Irisin,Nesfatin-1 and YKL-40 levels in evaluating the progression of MS patients were 0.844,0.849 and 0.823,respectively,which were lower than the AUC(0.957)of their combination(Z=3.158,3.096,3.324,all P<0.05).Conclusion Serum Irisin,Nesfatin-1 and YKL-40 detection levels can effectively evaluate the progression of MS patient condition.